GlassScriptPhysician profile
Darren Christopher Spearman
NPI 1851323034
$8,321.38
in general payments reported to CMS, 2019-2025
32 companies · $2,092 in 2025
The $2,092 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,144 · 2020: $583 · 2021: $442 · 2022: $980 · 2023: $1,287 · 2024: $1,793 · 2025: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,080 · Education: $92.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,080.09 |
| Education | $92.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,771.85 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $797.91 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $647.68 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $637.40 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $523.81 | 2019-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $465.02 | 2019-2025 | |
| Pfizer INC. | $452.45 | 2019-2025 | |
| Celgene Corporation | $292.79 | 2022-2023 | Zeposia |
| Genzyme Corporation | $210.22 | 2022-2025 | |
| Lilly USA, LLC | $183.01 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $158.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $158.49 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $153.22 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $150.84 | 2024-2025 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $98.13 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $86.63 | 2019-2024 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $64.70 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $61.48 | 2019-2023 | Rebyota |
| Evoke Pharma, INC. | $54.29 | 2022-2025 | Gimoti |
| Ironwood Pharmaceuticals, INC | $54.04 | 2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $52.89 | 2023-2024 | Dupixent |
| Redhill Biopharma INC. | $45.70 | 2021-2023 | Talicia |
| Celltrion USA INC. | $40.01 | 2024-2025 | Vegzelma, Zymfentra |
| Shire North American Group INC | $32.89 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $25.47 | 2019 | |
| Vivus LLC | $21.26 | 2025 | Pancreaze |
| Daiichi Sankyo INC. | $18.35 | 2021 | |
| Alcresta Therapeutics, INC. | $17.48 | 2023 | Relizorb |
| Merck Sharp & Dohme LLC | $17.09 | 2023 | Dificid |
| Olympus America INC. | $14.65 | 2021 | |
| Shionogi INC | $12.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$83,021.63 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Spearman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.